8-K: BioAffinity Technologies Reports Q2 2026 Growth

BioAffinity Technologies announced strong second quarter 2026 results, with CyPath Lung test volume surging 216% year-over-year and revenue increasing 19%, while advancing its diagnostic and therapeutic pipeline.

Summary

• BioAffinity Technologies reported financial results for the second quarter ended June 30, 2026.
• CyPath Lung diagnostic test volume increased by 216% year-over-year in Q2 2026.
• Testing revenue for CyPath Lung in the first six months of 2026 was approximately $835,000, a 159% increase from the prior year's $323,000.
• The company delivered 1,097 CyPath Lung test reports in the first six months of 2026, up from 390 in the same period of 2025.
• Physician office adoption of CyPath Lung increased by 122% in Q2 2026 compared to Q2 2025.
• Revenue for Q2 2026 was $1.5 million, a 19% increase from $1.3 million in Q2 2025.
• Net loss for Q2 2026 was $3.4 million, an improvement from a net loss of $4.1 million in Q2 2025.
• Cash and cash equivalents were $2.4 million as of June 30, 2026, down from $6.4 million as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, driven by significant growth in test volumes and revenue for CyPath Lung, alongside progress in clinical trials and pipeline development, despite continued net losses.

Positives

• Significant year-over-year growth in CyPath Lung test volume (216% in Q2 2026).
• Substantial increase in CyPath Lung testing revenue for the first six months of 2026 ($835,000, up 159%).
• Growing physician adoption of CyPath Lung, with a 122% increase in ordering offices/clinics in Q2 2026.
• Revenue for Q2 2026 increased by 19% to $1.5 million.
• Reduced net loss in Q2 2026 to $3.4 million, compared to $4.1 million in Q2 2025.
• Positive preliminary therapeutic data for topical treatments for skin cancers.
• Advancement in pipeline for precision diagnostics for asthma and COPD.
• Successful public offering in June 2026 raising approximately $3.2 million.

Negatives

• Continued net loss for the quarter ($3.4 million).
• Significant decrease in cash and cash equivalents to $2.4 million from $6.4 million.
• Operating expenses increased to $4.8 million in Q2 2026 from $3.8 million in Q2 2025.
• Selling, general and administrative expenses increased to $2.9 million from $2.2 million.

Risks

• The company's ability to successfully commercialize CyPath Lung and achieve broader market acceptance.
• The company's ability to obtain adequate financing to fund operations and development activities.
• Risks related to the results of clinical trials and studies.
• The company's ability to obtain and maintain regulatory approvals or clearances.
• The company's ability to protect its intellectual property.
• Competition from other companies developing similar products.
• Changes in applicable laws or regulations.
• The company's limited operating history and history of operating losses.

Future Outlook

The company's priorities for the second half of 2026 include expanding physician adoption, increasing utilization among existing customers, and introducing CyPath Lung to new healthcare systems and specialty practices. They also anticipate advancing their pipeline of precision diagnostics and therapeutics for skin cancers.

Management Comments

• "Our commercial strategy continues to gain significant traction as physicians increasingly recognize the clinical value of CyPath Lung for evaluating patients at high risk for lung cancer and surveilling lung cancer survivors for recurrence."
• "During the second quarter, CyPath Lung test volume surged 216% year-over-year. This growth reflects accelerating physician adoption and clinical confidence in our technology."
• "By leveraging our expertise in flow cytometry and AI and our work with siRNAs, we are building a robust pipeline of precision diagnostics for the large asthma and COPD markets and even larger therapeutic markets for topically delivered drugs that treat squamous and basal cell skin cancers."
• "Looking ahead, our priorities for the second half of 2026 are expanding physician adoption, increasing utilization among existing customers, and introducing CyPath Lung to new healthcare systems and specialty practices, including oncology."
• "We believe this balanced approach positions bioAffinity to create lasting value for patients, healthcare providers and shareholders."

Industry Context

StockSavvy.ai notes that bioAffinity Technologies is operating in the competitive and rapidly evolving fields of early cancer detection and precision medicine. The significant growth in CyPath Lung test volume indicates increasing market acceptance for non-invasive diagnostic tools, a trend also seen with competitors developing similar technologies for various cancers and diseases.

Stakeholder Impact

• Shareholders: Potential for increased value driven by commercial growth and pipeline development, but offset by continued losses and reduced cash reserves. The company is also addressing a delisting determination notice from Nasdaq.
• Healthcare Providers: Increased availability and adoption of CyPath Lung, providing a tool for earlier and more accurate lung cancer detection.
• Patients: Potential for earlier and more accurate diagnosis of lung cancer, leading to better treatment outcomes and avoidance of unnecessary invasive procedures.
• Suppliers: Increased demand for laboratory supplies and services due to higher test volumes and R&D activities.

Next Steps

• Expand physician adoption of CyPath Lung.
• Increase utilization among existing CyPath Lung customers.
• Introduce CyPath Lung to new healthcare systems and specialty practices.
• Advance the development of precision diagnostics for asthma and COPD.
• Advance the development of topically delivered therapeutics for skin cancers.

Key Dates

Recommendation

The company shows strong commercial momentum with significant growth in its core product, CyPath Lung, and is advancing its pipeline. However, continued operating losses, a substantial decrease in cash reserves, and the ongoing Nasdaq delisting notice warrant a cautious approach. The positive developments are balanced by significant financial and operational risks, suggesting a 'hold' position until further clarity on financing and regulatory matters emerges.

Keywords

CyPath Lung, lung cancer detection, biotechnology, diagnostic test, flow cytometry, precision diagnostics, skin cancer therapeutics, asthma diagnostics